The library
Guides
25 pieces on what the research shows, how people stay safe, where the law stands, and what happens after the experience.
Psilocybin Clinical Trial Results: How the Studies Worked and What They Found
How psilocybin trials are designed and how to read their results: comparison groups, blinding, response versus remission, how long effects lasted, who was excluded and side effects.
6 min read
MDMA Therapy for PTSD: History, Trials and the FDA Decision
How MDMA went from 1970s therapy rooms to Schedule I to phase 3 trials, how the protocol worked, why the FDA declined it in 2024, and the lawful options as of October 2026.
ReadCulture & historyPeyote: Cultural Significance and Sacred Traditions
Peyote's 5,700-year history, the Wixárika pilgrimage to Wirikuta, the Native American Church and the law that protects it, and why the cactus is now Vulnerable.
ReadHarm reductionHarm Reduction Basics: A Practical Guide to Safer Use
Where harm reduction comes from, the main risks of classic psychedelics as studies describe them, what lowers those risks, and when to call for emergency help.
ReadHarm reductionSet and Setting: The Most Important Variables in a Psychedelic Experience
Where the idea of set and setting came from, what studies show about mindset and surroundings, how trials control them, and how retreats differ.
ReadTherapy & integrationIntegration Practices: Making Sense of Psychedelic Experiences
What integration means in clinical trials and Oregon law, what the evidence does and does not show, common practices, warning signs and how to choose an integration therapist.
ReadLegalLegal Status of Psychedelics by Country: 2026 Overview
How the 1971 UN Convention treats DMT, psilocybin and mescaline, why plants fall outside it, and how national laws on ayahuasca, mushrooms, peyote and ibogaine then diverge.
ReadResearchMicrodosing Research Review: What Science Actually Shows
What placebo-controlled and self-blinding studies of LSD and psilocybin microdosing found, why expectancy explains much of the reported benefit, the open safety questions and the law.
ReadTherapy & integrationPsychedelic-Assisted Therapy: A Comprehensive Overview
How psychedelic-assisted therapy works as a treatment model, what therapists do, the lawful routes as of October 2026, what it costs, the ethics concerns and how to judge a provider.
ReadResearchDMT and the Brain: What Neuroscience Reveals
What DMT is, where it occurs, why ayahuasca needs an MAO inhibitor, what the Strassman and Imperial brain studies found, and what the first depression trials show.
ReadCulture & historyLSD: History, Science, and Modern Research
Hofmann's discovery, Sandoz's Delysid, MKUltra, prohibition and the modern trials, including the 2026 phase 3 results for generalised anxiety, with what is and is not proven.
ReadTherapy & integrationKetamine Therapy for Depression: What You Need to Know
Ketamine's path from 1960s anaesthetic to depression treatment, how it may work, which forms are FDA approved and which are off-label, what a course involves, and the risks.
ReadResearchIbogaine for Addiction Treatment: Promise and Risk
Ibogaine's history from Bwiti ritual to addiction self-help, why drug development stalled, how the studies were done, its cardiac risk, the law by country and Texas's trial funding.
ReadHarm reductionPsychedelic Safety Checklist: Before, During, and After
What to check about a retreat or licensed session before you book, on the day and afterwards: licence, screening, staff, emergency plan, consent, the law and aftercare.
ReadHarm reductionDrug Interaction Warnings: Psychedelics and Medications
Why some medicines and psychedelics are a dangerous mix: serotonin syndrome, MAO inhibition, lithium seizures, stimulants and blood pressure, ibogaine and the heart, ketamine and sedatives.
ReadHarm reductionThe Trip Sitter's Guide: How to Support Someone Safely
The sitter's side of a psychedelic session: the role, consent and touch, what to prepare, what to watch for, what not to do, and when to call for help.
ReadCulture & historyThe Psychedelic Renaissance: A Timeline of Key Milestones
A dated, sourced timeline from Hofmann's LSD in 1938 and 1943 through prohibition, the 2006 restart, Oregon and Colorado, the 2024 MDMA rejection and what changed in 2025 and 2026.
ReadCulture & historyIndigenous Use and Cultural Respect: An Ethical Framework
The traditions behind ayahuasca, mushrooms, iboga and peyote, the problems that outside demand creates for them, and what to ask a retreat about its relationship with Indigenous communities.
ReadLegalDecriminalization vs Legalization: Understanding the Difference
Decriminalisation, depenalisation, regulated supply and medical access explained through real laws: Portugal, Oregon's Measures 109 and 110, Colorado, US city resolutions, Australia and Czechia.
ReadResearchPsychedelic Research Institutions: Who Is Doing the Work
The university centres, non-profits, companies and public funders behind psychedelic trials, which studies each produced, and how to read who paid for a study.
ReadHarm reductionHow to Prepare for a Psychedelic Experience
Practical preparation for a lawful setting: choosing where, medical screening, the weeks before, deposits and travel, what to bring and what to ask the provider.
ReadHarm reductionChallenging Psychedelic Experiences and How to Handle Them
What a difficult trip involves, how common it is, what helps in the moment, when it becomes a medical emergency, and where to get help if problems last.
ReadResearchNeuroplasticity and Psychedelics: How They Rewire the Brain
Psychedelics grow new neural connections in cells and mice. What has been shown in humans is far thinner. A guide to the plasticity evidence and its limits.
ReadResearchPsychedelics and Creativity: What the Research Shows
From the 1966 problem-solving study to placebo-controlled microdosing trials: what tests of creativity actually show, why they differ from what users report, and the risks.
ReadResearchThe Future of Psychedelic Medicine: What to Expect
What is pending as of October 2026, from psilocybin and LSD applications to MDMA after its rejection, and the open problems that will decide how far psychedelic medicine goes.
Read